Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
By G. Schindler, D. Capper, Jochen Meyer, W. Janzarik, H. Omran, C. Herold‐Mende, K. Schmieder, P. Wesseling, C. Mawrin, M. Hasselblatt and 7 more. Acta Neuropathologica, 2011
963 citations recorded by the source corpus.
Subfields: Genetics, Neurology, Ophthalmology
View Paper: https://www.semanticscholar.org/paper/87e2dbf9079b89c18909a854e094d447c91f4a98
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy (2012, background): “Recently, high BRAFmutations were reported in pleomorphic xanthoastrocytomas and gangliogliomas [47], colon carcinomas and in other tumor types (Table 2).”
- Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “In GBMs, BRAF V600E mutations have been detected in approximately 5 % of the cases [85, 142].”
- Glioma Subclassifications and Their Clinical Significance (2017, background): “BRAF mutation can be seen in 20% to 50% of gangliogliomas of the brain [62, 64].”